Pulmonary MALT Lymphoma — the primary pulmonary form of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT), arising from bronchus-associated lymphoid tissue (BALT) in the lung parenchyma and representing the second or third most common anatomical site for MALT lymphoma after the stomach and, in some series, the salivary glands — is a rare, indolent B-cell non-Hodgkin lymphoma constituting approximately 0.5–1% of all non-Hodgkin lymphomas and 70–90% of all primary pulmonary lymphomas, with an estimated incidence of 0.1–0.2 per 100,000 person-years in the general population and a substantially elevated incidence among patients with systemic autoimmune conditions — particularly Sjögren's syndrome (conferring a 44-fold increased MALT lymphoma risk), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) — where the pathogenesis parallels the gastric MALT lymphoma model of chronic antigen stimulation of bronchial mucosa-infiltrating B cells by persistent antigenic stimulation (autoimmune or infectious, as in the rare cases of BALT-MALT arising in the context of Mycoplasma pneumoniae or other pulmonary infections), leading to the acquisition of organized lymphoid tissue in the bronchial mucosa that is physiologically absent (BALT — bronchus-associated lymphoid tissue — being inducible by infection or autoimmune stimulation in the normal human lung, unlike the mucosa-associated lymphoid tissue of the gut, providing the biological substrate for pulmonary MALT lymphoma development); molecularly characterized by chromosomal translocations including t(14;18)(q32;q21)/IGH-MALT1 (the most prevalent translocation in pulmonary MALT, found in approximately 20–40% of cases — substantially more common in pulmonary than in gastric MALT where t(11;18) dominates), t(11;18)(q21;q21)/BIRC3-MALT1 (found in 5–20% of pulmonary MALT — less common than in gastric MALT but still clinically significant as a potential predictor of treatment resistance), t(3;14)(p14;q32)/FOXP1-IGH (found in a minority of pulmonary MALT, associated with greater histological complexity), and somatic mutations in TNFAIP3/A20, KMT2D/MLL2, and CREBBP, with the immunophenotype of CD20-positive, CD3-negative, CD5-negative, CD10-negative, cyclin D1-negative marginal zone B cells with variable plasma cell differentiation (particularly in autoimmune-associated cases) distinguishing pulmonary MALT from mantle cell lymphoma, primary pulmonary follicular lymphoma, lymphomatoid granulomatosis, and chronic lymphocytic leukemia with pulmonary involvement; clinically presenting with the highly characteristic pattern of indolent, often asymptomatic bilateral pulmonary infiltrates, consolidations, or mass lesions discovered incidentally on chest CT performed for unrelated indications in the majority of patients — with cough, dyspnea, and non-specific respiratory symptoms in a minority, and B symptoms (fever, night sweats, weight loss) being distinctly uncommon in the primary, low-grade form — with radiological appearances including bilateral patchy consolidations (the most common pattern — representing alveolar filling by neoplastic marginal zone B cells, frequently containing air bronchograms), ground-glass opacities, pulmonary nodules or masses (single or multiple), and the "reversed halo" sign in a minority; staged by the Lugano staging system adapted for primary pulmonary lymphoma (Stage I: single lung or single lobe; Stage II: bilateral pulmonary involvement or mediastinal adenopathy; Stage IV: extrapulmonary involvement including bone marrow, peripheral blood, or distant lymph nodes); diagnosed by CT-guided percutaneous core needle biopsy (the primary diagnostic approach for radiologically accessible lesions — superior to bronchoscopy with transbronchial biopsy for lymphoma diagnosis, which has sensitivity of only 30–50% for peripheral consolidations but 70–80% for central/endobronchial lesions), video-assisted thoracoscopic surgery (VATS) resection biopsy (for lesions inaccessible to CT-guided biopsy or when surgical resection is planned as therapy), or cryobiopsy via endobronchial ultrasound (EBUS) or bronchoscopy (emerging technique for accessible central lesions); and managed by a risk-stratified approach based on the disease's exceptional indolence — with an observation-only strategy being appropriate for asymptomatic patients with low-volume bilateral disease (overall survival at 10 years exceeding 70–80%, with a substantial proportion of patients never requiring active treatment), surgical resection (lobectomy or wedge resection) for anatomically localized, symptomatic, or resectable single-lobe disease (achieving long-term remission in >80% of resected patients), involved-field radiation therapy (IFRT, 24–30 Gy) for localized unilateral disease in patients who are surgical candidates or declining surgery, rituximab monotherapy (375 mg/m² weekly × 4, or extended to monthly maintenance for 2 years in some protocols) for symptomatic or progressive bilateral disease, and chemoimmunotherapy (R-chlorambucil, R-bendamustine, or R-CHOP) for systemic, progressive, or histologically transformed disease — with the critical caveat that DLBCL transformation (occurring in 5–10% of pulmonary MALT patients over long follow-up, manifesting as rapidly enlarging pulmonary mass, new B symptoms, LDH elevation, and diffuse large B-cell morphology on repeat biopsy) requires immediate escalation to aggressive chemoimmunotherapy.
Pulmonary MALT lymphoma technology platforms — whether supporting the pulmonary oncology and thoracic surgery programs performing the diagnostic workup (chest CT with contrast for initial characterization and staging, PET-CT for metabolic activity assessment and extrapulmonary staging, CT-guided core needle biopsy for histological diagnosis, EBUS for central lesions and mediastinal staging, VATS for surgical diagnosis and therapy); molecular pathology platforms executing the MALT translocation FISH panel (t(14;18)/IGH-MALT1, t(11;18)/BIRC3-MALT1, t(3;14)/FOXP1-IGH), B-cell clonality analysis by immunoglobulin gene rearrangement PCR (essential for distinguishing lymphoma from reactive BALT in autoimmune patients with organized bronchial lymphoid infiltrates), CD20 and cyclin D1 IHC (mantle cell lymphoma exclusion), and MYC/BCL2 FISH for transformation surveillance; radiation oncology platforms coordinating IFRT for localized pulmonary MALT; rituximab infusion platforms managing biological therapy for symptomatic bilateral or systemic disease; rheumatology co-management platforms for the substantial subset of patients with concurrent Sjögren's syndrome, SLE, or RA; clinical imaging platforms managing the serial CT surveillance that detects disease progression or transformation in observation-managed patients; or patient communication platforms coordinating the active surveillance protocol and cold-avoidance or autoimmune disease management education for autoimmune-associated pulmonary MALT — must maintain the availability and performance standards that pulmonary MALT lymphoma's imaging-based surveillance cadence, CT-guided biopsy precision, molecular pathology stratification, and transformation detection urgency demand. This guide explains why pulmonary MALT lymphoma care tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the radiological surveillance precision, molecular pathology stratification, surgical and radiation therapy coordination, and transformation vigilance of the most indolent primary pulmonary lymphoma.
Why Pulmonary MALT Lymphoma Care Tech Platforms Require Specialized Monitoring Attention
Pulmonary MALT lymphoma management is distinguished by the exceptional indolence and observation-feasibility of the disease — where the majority of asymptomatic patients are appropriately managed by serial CT surveillance without active treatment, and where the platform-enabled imaging surveillance schedule is the primary means of detecting the progression or transformation that triggers therapeutic intervention; by the diagnostic precision imperative — where distinguishing true pulmonary MALT lymphoma from reactive BALT hyperplasia in Sjögren's syndrome or other autoimmune conditions, from primary pulmonary follicular lymphoma, from lymphomatoid granulomatosis (a CD20-positive EBV-driven T-cell lymphoproliferative disorder with angiocentric lung infiltrates), and from DLBCL with pulmonary involvement requires CT-guided core biopsy with comprehensive IHC and B-cell clonality analysis that cannot fail; by the MALT translocation stratification relevance — where t(14;18)/IGH-MALT1 detection and t(11;18)/BIRC3-MALT1 status inform treatment selection in patients requiring active therapy; and by the transformation surveillance urgency — where DLBCL transformation in a pulmonary MALT patient on observation-only management requires immediate histological documentation of the transition from an indolent, observation-appropriate lymphoma to an aggressive lymphoma requiring urgent R-CHOP. Technology failures create disruptions calibrated to the CT surveillance schedule compliance, CT-guided biopsy coordination, molecular pathology diagnostic precision, radiation therapy delivery accuracy, and transformation detection urgency of the most indolent primary pulmonary lymphoma.
CT and PET imaging platforms are the primary surveillance infrastructure for observation-managed pulmonary MALT. The majority of pulmonary MALT patients — particularly those with bilateral, asymptomatic, low-volume disease — are managed by a protocol of serial CT chest with contrast every 3–6 months for the first 2 years, then every 6–12 months thereafter, with PET-CT reserved for evaluation of metabolic activity changes or clinical concern for transformation. CT imaging platforms must support surveillance scheduling at defined intervals, radiologist reporting of bilateral pulmonary consolidation or nodule progression with SUVmax-capable standardized reporting when PET-CT is performed, size measurement documentation with RECIST criteria or LYRIC criteria tracking for lymphoma, and multi-timepoint comparison display for longitudinal progression assessment. A CT platform failure during the surveillance window for a patient with bilateral pulmonary consolidations last measured 14 months ago delays the only means of detecting new progression or developing transformation. Monitor CT and PET imaging platforms at 2-minute intervals during clinical hours.
CT-guided biopsy coordination platforms enable the histological diagnosis that initiates the entire management algorithm. CT-guided percutaneous core needle biopsy — the primary diagnostic procedure for pulmonary MALT with peripheral or accessible parenchymal lesions — requires procedural scheduling, CT fluoroscopy or real-time CT guidance reservation, interventional radiology resource coordination, coagulation profile and platelet count verification prior to biopsy, pneumothorax management protocol availability, specimen routing to cytopathology for rapid adequacy assessment and to surgical pathology for full IHC and molecular workup, and post-procedure chest X-ray monitoring. A CT-guided biopsy coordination platform failure delays the initial histological diagnosis for a patient with new bilateral pulmonary consolidations and bilateral hilar adenopathy who is unable to undergo bronchoscopy. Monitor CT-guided biopsy coordination platforms at 2-minute intervals during interventional radiology scheduling hours.
Molecular pathology platforms perform the diagnostic and stratification tests that distinguish pulmonary MALT from its histological mimics and determine translocation status. The B-cell clonality analysis by IgH VDJ PCR (European BIOMED-2 protocol or equivalent — identifying clonal B-cell population in a background of reactive BALT infiltrate in Sjögren's syndrome or other autoimmune conditions where the distinction between reactive and neoplastic is the central diagnostic challenge), MALT translocation FISH panel (t(14;18)/IGH-MALT1 most prevalent; t(11;18)/BIRC3-MALT1; t(3;14)/FOXP1-IGH), comprehensive IHC panel (CD20, CD3, CD5, CD10, cyclin D1, BCL2, BCL6, MUM1, Ki-67, MYC IHC for transformation screening), and MYC FISH and BCL2/BCL6 FISH for transformation confirmation in any biopsy with large B-cell morphology cannot fail during the initial workup or surveillance. Monitor molecular pathology platforms at 2-minute intervals during business and urgent biopsy hours.
Thoracic surgery platforms coordinate the VATS resection that simultaneously diagnoses and treats localized pulmonary MALT. For single-lobe pulmonary MALT where the diagnosis is uncertain on CT-guided biopsy or where surgical resection is the planned therapeutic approach (achieving long-term remission in >80% of resected patients), VATS lobectomy or wedge resection requires thoracic surgery scheduling, anesthesia coordination, intraoperative frozen section with immediate lymphoma versus reactive distinction assessment, specimen routing to molecular pathology, pulmonary function testing prior to resection planning (ensuring adequate post-resection FEV1 and DLCO for patients with underlying autoimmune pulmonary involvement), and postoperative pulmonary rehabilitation coordination. Monitor thoracic surgery coordination platforms at 2-minute intervals during preoperative and perioperative hours.
Radiation oncology platforms coordinate IFRT for localized unilateral pulmonary MALT. Involved-field radiation therapy (IFRT, 24–30 Gy in 12–20 fractions) delivers highly effective local control (>90%) for anatomically localized unilateral pulmonary MALT. Pulmonary IFRT coordination requires 4DCT simulation (to account for respiratory motion in pulmonary field planning), respiratory-gated or breath-hold treatment delivery to minimize cardiac and uninvolved pulmonary dose, involved-site field design documenting gross tumor volume (GTV — consolidation/mass plus any FDG-avid regional adenopathy), clinical target volume (CTV — GTV plus 0.5–1.0 cm margin), and planning target volume (PTV — CTV plus respiratory and setup margin), pulmonary function monitoring before and after treatment, and post-radiation CT surveillance at 3 months. Monitor radiation oncology coordination platforms at 2-minute intervals during active radiation delivery.
Rituximab infusion platforms coordinate systemic therapy for bilateral or symptomatic pulmonary MALT. Rituximab monotherapy (375 mg/m² weekly × 4, with optional 2-year monthly maintenance) for symptomatic or progressive bilateral pulmonary MALT, or combined R-bendamustine or R-chlorambucil for more aggressive disease, requires pre-infusion hepatitis B screening (HBsAg and HBcAb — with antiviral prophylaxis for HBcAb-positive patients), infusion reaction monitoring and management, pulmonary function test monitoring after treatment (given the autoimmune pulmonary context in Sjögren's-associated cases where rituximab may affect B-cell-mediated pulmonary autoimmunity), and post-treatment CT response assessment at 3 months. Monitor rituximab infusion platforms at 1-minute intervals during active administration.
Rheumatology co-management platforms coordinate the autoimmune disease management in Sjögren's-associated pulmonary MALT. For the substantial subset of pulmonary MALT patients with concurrent Sjögren's syndrome — where rituximab used for the lymphoma also provides beneficial effects on the autoimmune disease, and where the autoimmune disease activity may influence the decision between observation and treatment for indolent pulmonary MALT — rheumatology platforms must coordinate Sjögren's disease activity scoring (EULAR-SS Disease Activity Index — ESSDAI), anti-SSA/SSB antibody levels, labial salivary gland biopsy focal score tracking, pilocarpine or hydroxychloroquine prescribing, and rituximab coordination for dual lymphoma and autoimmune treatment goals. Monitor rheumatology co-management platforms at 2-minute intervals during joint pulmonary-rheumatology conference and clinical hours.
What to Monitor on a Pulmonary MALT Lymphoma Care Tech Platform
CT and PET Imaging Surveillance
Monitor CT chest surveillance scheduling documentation (3-month intervals for first 2 years post-diagnosis for untreated patients, or post-treatment response assessment; 6-month intervals for established stable observation-phase patients; immediate CT for new respiratory symptoms or clinical concern for progression), CT report delivery for bilateral pulmonary consolidation and nodule size measurement with multi-timepoint comparison documentation (RECIST/LYRIC criteria for lesion tracking — longest diameter measurement for index lesions, sum of lesions calculation), PET-CT result routing for metabolic activity assessment (SUVmax documentation for progressive or transformed lesions; comparison of SUVmax at baseline and at surveillance), CT progression criteria notification (≥20% increase in sum of longest diameters of index lesions — RECIST progressive disease; or new lesions; or B symptom onset), radiologist radiology-oncology multidisciplinary lung tumor board scheduling for complex or progressing cases, chest X-ray result routing for post-procedure monitoring after CT-guided biopsy, and urgent imaging ordering workflow availability for patients reporting acute respiratory decompensation or new hemoptysis at 2-minute intervals during clinical hours.
CT-Guided Biopsy and Surgical Biopsy Coordination
Monitor CT-guided biopsy scheduling documentation (interventional radiology scheduling, CT fluoroscopy or CT-guided room reservation, pre-procedure coagulation documentation — INR <1.5, platelet count >75 × 10⁹/L for core needle biopsy), pneumothorax management protocol documentation (chest tube placement criteria — pneumothorax >2 cm or symptomatic — chest radiology unit coordination), cytopathology rapid adequacy assessment result routing (confirming diagnostic core tissue with sufficient lymphoid cells for IHC before procedure termination), specimen routing to molecular pathology (MALT translocation FISH requisition submitted at time of biopsy; IgH clonality requisition submitted for Sjögren's-associated cases), VATS scheduling documentation (thoracic surgery OR scheduling, anesthesia consultation, PFT verification), intraoperative frozen section result routing (lymphoma vs. reactive distinction for operative management decision), and post-biopsy chest X-ray result routing for pneumothorax surveillance at 2-minute intervals during interventional radiology scheduling and procedural hours.
Molecular Pathology and MALT Translocation Panel
Monitor B-cell clonality analysis by IgH VDJ PCR result routing (clonal IgH rearrangement detection in pulmonary biopsy specimens — critical for Sjögren's-associated cases where reactive BALT vs. MALT lymphoma distinction requires molecular evidence of B-cell clonality), MALT translocation FISH panel result routing (t(14;18)(q32;q21)/IGH-MALT1 — most prevalent in pulmonary MALT, reporting of MALT1 and IGH signal ratio; t(11;18)(q21;q21)/BIRC3-MALT1 — with clinical interpretation of treatment resistance implications; t(3;14)(p14;q32)/FOXP1-IGH), comprehensive IHC result routing (CD20 positivity — rituximab eligibility; CD5 negativity — CLL exclusion; CD10 negativity — follicular lymphoma exclusion; cyclin D1 negativity — mantle cell lymphoma exclusion; MYC IHC for transformation screening; Ki-67 proliferation index — low-grade MALT typically <10%), MYC FISH result routing (transformation detection — MYC rearrangement indicating large B-cell evolution), BCL2 and BCL6 FISH result routing (double-hit/triple-hit assessment for confirmed DLBCL transformation), EBV EBER ISH result routing (lymphomatoid granulomatosis exclusion — EBER-negative in MALT, EBER-positive in LYG), and interdisciplinary pathology-pulmonology-hematology-oncology conference scheduling for integrated molecular-pathologic result discussion at 2-minute intervals during business and urgent biopsy hours.
Radiation Oncology Coordination
Monitor 4DCT simulation scheduling (with documentation of respiratory motion amplitude for each pulmonary GTV across 10 respiratory phases — informing respiratory gating threshold selection), IFRT field design review documentation (pulmonary GTV/CTV/PTV contouring review by thoracic radiation oncologist; spinal cord and heart dose constraint verification — maximum heart dose <26 Gy, mean lung dose <20 Gy with V20 <30% for bilateral disease), respiratory gating or breath-hold delivery documentation (respiratory gating waveform acquisition and gate threshold documentation), radiation delivery session tracking (fraction number, daily dose, cumulative dose, any fraction holds for acute pulmonary toxicity — dyspnea, hypoxia, pneumonitis), acute and late pulmonary toxicity monitoring documentation (CTCAE grade 1–4 radiation pneumonitis grading; steroid initiation for grade ≥2 pneumonitis), and post-IFRT CT response assessment scheduling at 3 months at 2-minute intervals during active radiation delivery.
Rituximab and Systemic Therapy Management
Monitor hepatitis B reactivation risk assessment result routing (HBsAg positive — absolute contraindication to rituximab without antiviral therapy; HBcAb positive — antiviral prophylaxis with entecavir or tenofovir for duration of rituximab plus 12 months post-completion; HBV DNA baseline before therapy; monthly HBV DNA monitoring during treatment and for 12 months after), rituximab pre-infusion vital signs and symptom documentation, infusion reaction monitoring (grade I–II: slowing infusion rate, supplemental antihistamine; grade III–IV: stop infusion, epinephrine, emergency protocol, corticosteroid), weekly rituximab 4-dose completion documentation with dose documentation (375 mg/m² per infusion with BSA calculation), monthly maintenance rituximab scheduling (where applicable — some protocols use 375 mg/m² monthly × 24 months for bilateral or high-burden pulmonary MALT), pulmonary function test monitoring after rituximab (autoimmune pulmonary involvement assessment — DLCO and FEV1 at 3-month post-treatment surveillance), IgG quantification at 6 and 12 months post-rituximab (post-rituximab hypogammaglobulinemia monitoring with IVIG replacement documentation for IgG <400 mg/dL), and CT response assessment at 3 months after systemic therapy completion at 1-minute intervals during active rituximab administration.
Rheumatology Co-Management
Monitor Sjögren's syndrome disease activity documentation (ESSDAI score tracking — systemic Sjögren's disease activity across 12 domains including pulmonary, renal, peripheral nervous system, and lymphoproliferative domains; ESSDAI ≥14 indicating highly active systemic Sjögren's requiring aggressive treatment of both autoimmune disease and lymphoma), anti-SSA/SSB antibody titer routing (baseline and after rituximab — rituximab induces anti-SSA/SSB reduction indicating B-cell depletion in autoimmune compartment), labial salivary gland biopsy focal score (≥1 focus/4 mm² confirming Sjögren's; tracking after rituximab therapy), ESSPRI patient symptom score (dryness, fatigue, pain — treatment response in Sjögren's component), ophthalmology Schirmer's test and slit-lamp routing (sicca severity assessment), pulmonary HRCT for interstitial lung disease monitoring (Sjögren's-associated ILD — typically LIP or NSIP pattern — vs. MALT lymphoma consolidation distinction), and joint pulmonary-rheumatology multidisciplinary board scheduling for unified Sjögren's-pulmonary MALT management decisions at 2-minute intervals during joint clinical conference hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Pulmonary MALT lymphoma care requires simultaneous platform access across pulmonary oncology and thoracic medicine (disease staging, CT surveillance management, treatment decision-making), interventional radiology (CT-guided biopsy coordination), thoracic surgery (VATS diagnostic and therapeutic resection), molecular pathology (MALT translocation FISH, IgH clonality, IHC, transformation monitoring), radiation oncology (IFRT planning and delivery for localized disease), hematology-oncology (rituximab and systemic therapy), rheumatology (Sjögren's syndrome co-management), radiology (serial CT and PET-CT surveillance), and nuclear medicine (PET-CT metabolic staging). Authentication failures simultaneously block the interventional radiologist coordinating CT-guided biopsy for the newly presenting patient with bilateral pulmonary consolidations, the molecular pathologist reporting IgH clonality analysis distinguishing MALT lymphoma from reactive BALT in a Sjögren's syndrome patient, and the hematology-oncologist managing rituximab for progressive bilateral disease — disrupting the sequential diagnostic and therapeutic chain.
SSL Certificates
Monitor SSL certificate expiry across patient portals, CT and PET imaging scheduling platforms, interventional radiology coordination systems, molecular pathology reporting environments, radiation therapy planning systems, rituximab infusion management systems, rheumatology co-management platforms, and clinical trial management systems. Certificate errors disrupt the CT surveillance scheduling, CT-guided biopsy coordination, molecular pathology reporting, and systemic therapy management workflows of a disease whose management depends on sustained multi-system platform access across pulmonary oncology, molecular pathology, and rheumatology.
HIPAA and Oncology Data Privacy Considerations
Pulmonary MALT lymphoma technology platforms handle sensitive PHI including primary pulmonary lymphoma diagnoses with autoimmune disease associations (Sjögren's syndrome, SLE, RA — diseases with substantial life insurance and employment discrimination implications), chest CT and PET-CT imaging reports with pulmonary consolidation and nodule characterization, CT-guided biopsy reports with lymphoma diagnosis, B-cell clonality PCR results and MALT translocation FISH results (with genomic implications for the IGH, MALT1, BIRC3, and FOXP1 genes), autoimmune serology (anti-SSA/SSB antibody results), rituximab infusion records and hepatitis B serology documentation, radiation therapy treatment planning data including 4DCT simulation and respiratory gating parameters, and VATS surgical records. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components. The combination of pulmonary lymphoma diagnosis, systemic autoimmune disease documentation, genomic translocation data, and oncology treatment records in the same medical record creates a PHI profile requiring carefully managed access controls across pulmonary oncology, molecular pathology, radiation oncology, rheumatology, and hematology-oncology teams. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance.
Alerting Strategy for Pulmonary MALT Lymphoma Care Tech Platforms
Immediate alert during rituximab infusion: Rituximab infusion management platforms during active administration and post-infusion monitoring windows.
Immediate alert for confirmed DLBCL transformation: Transformation surveillance platforms when DLBCL transformation is pathologically confirmed requiring immediate chemoimmunotherapy escalation.
Sustained-failure alert (10–15 minutes): CT and PET imaging surveillance, CT-guided biopsy coordination, thoracic surgery coordination, molecular pathology, radiation oncology coordination, rituximab infusion management, and rheumatology co-management platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms pulmonary MALT lymphoma platform availability from the geographies where major pulmonary MALT programs — US academic thoracic oncology centers, European respiratory oncology centers with Sjögren's expertise, and East Asian thoracic surgery centers — concentrate.
Status Page for Pulmonary MALT Lymphoma Care Team Communication
A real-time status page gives pulmonary oncologists managing serial CT surveillance for observation-phase patients, interventional radiologists coordinating CT-guided biopsies, thoracic surgeons scheduling VATS for diagnostic and therapeutic resection, molecular pathologists reporting IgH clonality and MALT translocation FISH, radiation oncologists coordinating IFRT for localized disease, hematology-oncologists managing rituximab, rheumatologists co-managing Sjögren's syndrome, and clinical research coordinators managing pulmonary MALT trial enrollment immediate platform visibility without requiring inbound IT support contact. During a CT scheduling platform outage when a pulmonary oncologist is preparing to review the 6-month surveillance CT for a Sjögren's-associated bilateral pulmonary MALT patient on observation who had stable bilateral consolidations at the prior 3-month CT, a status page enables immediate telephone coordination with radiology scheduling and manual CT order entry while the platform is restored.
Include the status page URL in pulmonary MALT CT surveillance downtime procedures, interventional radiology CT-guided biopsy backup workflows, and radiation oncology contingency plans.
Vigilmon Setup for Pulmonary MALT Lymphoma Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Rituximab infusion management | 1 min | Slack + PagerDuty (infusion + post-infusion windows) | | CT and PET imaging surveillance scheduling | 2 min | Slack + PagerDuty (clinical hours) | | CT-guided biopsy coordination | 2 min | Slack + PagerDuty (IR scheduling hours) | | Molecular pathology / IgH clonality / MALT FISH | 2 min | Slack (business hours) | | Thoracic surgery / VATS coordination | 2 min | Slack + PagerDuty (perioperative hours) | | Radiation oncology / IFRT coordination | 2 min | Slack (active treatment hours) | | Rheumatology co-management (Sjögren's) | 2 min | Slack (clinical hours) | | Post-rituximab hypogammaglobulinemia monitoring | 2 min | Slack (clinical hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication at 1-minute intervals with 24/7 alerting
- Configure rituximab infusion management with 1-minute alerting during infusion and post-infusion monitoring
- Add CT and PET imaging surveillance scheduling with 2-minute alerting during clinical hours
- Configure CT-guided biopsy coordination with 2-minute alerting during interventional radiology scheduling hours
- Add molecular pathology platforms (IgH clonality PCR, MALT translocation FISH) with business-hours alerting
- Configure thoracic surgery and VATS coordination with perioperative-hours alerting
- Add radiation oncology coordination with 2-minute alerting during active IFRT delivery
- Configure rheumatology co-management platforms with clinical-hours alerting
- Add post-rituximab monitoring with clinical-hours alerting
- Enable SSL certificate monitoring across all clinical, imaging, and patient-facing domains
- Add the status page URL to pulmonary MALT CT surveillance downtime procedures and CT-guided biopsy backup workflows
Conclusion
Pulmonary MALT lymphoma technology platforms are embedded in the surveillance-intensive management paradigm of the most indolent primary pulmonary lymphoma — a disease where the majority of patients are managed by serial CT surveillance without active treatment, where platform-enabled imaging at precise 3–6 month intervals is the only means of detecting the progression or DLBCL transformation that changes the management from watchful waiting to active therapy, where the CT-guided biopsy coordination platform enables the histological diagnosis that initiates the entire clinical algorithm for a patient with bilateral pulmonary consolidations who cannot be assumed to have pulmonary MALT without molecular confirmation, and where the molecular pathology platform reporting IgH clonality analysis is the critical tool distinguishing true lymphoma from reactive BALT hyperplasia in the many Sjögren's syndrome patients who develop organized bronchial lymphoid infiltrates without developing malignant transformation — where the pulmonary oncologist must review the 6-month surveillance CT for a 58-year-old woman with bilateral pulmonary MALT on observation who had 14 bilateral consolidations at diagnosis ranging from 0.8 to 3.2 cm in longest diameter, who has been stable on 3-month surveillance CT for 18 months, with the 6-month CT now showing three new consolidations in the right lower lobe (2.4, 1.8, and 1.1 cm) and growth of the largest right upper lobe consolidation from 3.2 to 4.7 cm, triggering the decision between repeat CT-guided biopsy to exclude transformation and initiating rituximab for progressive pulmonary MALT; where the molecular pathologist must deliver the IgH clonality result for a 47-year-old man with Sjögren's syndrome and new bilateral pulmonary consolidations — showing clonal IgH VDJ rearrangement by BIOMED-2 PCR protocol (peak at 115 bp, reproducible in duplicate) in the CT-guided biopsy specimen, with MALT translocation FISH showing t(14;18)/IGH-MALT1 in 44% of analyzed cells, CD20-positive CD10-negative cyclin D1-negative marginal zone immunophenotype by IHC, and Ki-67 of 7% — establishing the diagnosis of pulmonary MALT lymphoma in a Sjögren's patient where the prior suspicion was reactive BALT hyperplasia, enabling discussion of observation vs. rituximab treatment with the hematology-oncology team; and where the radiation oncology platform must coordinate the 4DCT simulation and IFRT treatment planning for a 63-year-old woman with Stage I unilateral right lower lobe pulmonary MALT who underwent VATS wedge resection revealing positive surgical margin and t(11;18)/BIRC3-MALT1 by FISH, requiring post-operative IFRT of 24 Gy in 16 fractions to the right lower lobe bed with 4DCT-guided respiratory gating. A CT imaging scheduling platform failure during the 6-month surveillance window for an observation-managed bilateral pulmonary MALT patient delays the only radiological means of detecting new progression or consolidation growth in a patient whose clinical examination and serum LDH are normal by definition in this anatomically confined, indolent disease. A CT-guided biopsy coordination failure delays the definitive histological diagnosis for a patient with new bilateral consolidations who needs IgH clonality and MALT translocation FISH to distinguish pulmonary MALT from reactive BALT hyperplasia in their known Sjögren's syndrome.
Uptime monitoring gives pulmonary MALT lymphoma tech teams the detection capability to identify failures within seconds across CT and PET imaging surveillance scheduling, CT-guided biopsy coordination, molecular pathology reporting, thoracic surgery coordination, IFRT radiation planning and delivery, rituximab infusion management, and rheumatology co-management chains, trigger immediate clinical downtime procedures, and demonstrate to pulmonary oncology programs, interventional radiology units, thoracic surgery departments, molecular pathology laboratories, radiation oncology services, hematology-oncology teams, and compliance teams that the platform's operational reliability matches the CT surveillance precision, biopsy diagnostic accuracy, molecular stratification clarity, and transformation vigilance of the most indolent primary pulmonary lymphoma — a disease where platform availability at each surveillance and diagnostic step is not an IT performance metric but a clinical capability determining whether patients on observation receive the imaging result that prompts timely therapeutic intervention before symptomatic progression or undetected DLBCL transformation occurs.
Start monitoring your pulmonary MALT lymphoma care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #pulmonaryMALTlymphoma #MALTlymphoma #extranodal #marginalZoneLymphoma #BALT #bronchusAssociatedLymphoidTissue #primaryPulmonaryLymphoma #Sjogrens #autoimmune #rituximab #CTsurveillance #IFRT #radiationTherapy #DLBCLtransformation #RCHOP #hematologyOncology #pulmonaryOncology #thoracicSurgery #VATS #molecularPathology #FISH #IgHClonality #healthtech #digitalhealth #uptime #hipaa #cancertech #sre